Morgan Stanley cut its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 39.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 81,907 shares of the company’s stock after selling 53,822 shares during the quarter. Morgan Stanley owned 0.35% of Establishment Labs worth $1,518,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently made changes to their positions in the company. BlackRock Inc. lifted its position in Establishment Labs by 96.9% during the third quarter. BlackRock Inc. now owns 8,357 shares of the company’s stock valued at $155,000 after purchasing an additional 4,113 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Establishment Labs in the 3rd quarter worth approximately $217,000. GSA Capital Partners LLP lifted its holdings in shares of Establishment Labs by 54.7% in the 3rd quarter. GSA Capital Partners LLP now owns 24,440 shares of the company’s stock worth $453,000 after acquiring an additional 8,645 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Establishment Labs by 33.1% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 28,307 shares of the company’s stock worth $529,000 after acquiring an additional 7,033 shares during the last quarter. Finally, California Public Employees Retirement System bought a new stake in shares of Establishment Labs in the 2nd quarter worth approximately $807,000. Institutional investors and hedge funds own 54.29% of the company’s stock.
A number of equities research analysts have recently weighed in on ESTA shares. BTIG Research boosted their price objective on shares of Establishment Labs from $41.00 to $61.00 and gave the stock a “buy” rating in a report on Wednesday. BidaskClub upgraded shares of Establishment Labs from a “buy” rating to a “strong-buy” rating in a report on Friday, December 11th. Finally, Zacks Investment Research downgraded shares of Establishment Labs from a “hold” rating to a “sell” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Establishment Labs presently has an average rating of “Buy” and an average price target of $28.40.
Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.12. The business had revenue of $22.76 million for the quarter, compared to the consensus estimate of $22.50 million. Establishment Labs had a negative net margin of 46.40% and a negative return on equity of 49.51%. Equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.23 earnings per share for the current year.
In other news, COO Santos Salvador Dada sold 9,753 shares of the company’s stock in a transaction dated Tuesday, January 12th. The shares were sold at an average price of $50.51, for a total value of $492,624.03. Following the sale, the chief operating officer now directly owns 110,407 shares of the company’s stock, valued at approximately $5,576,657.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Quiros Juan Jose Chacon sold 4,577 shares of the company’s stock in a transaction dated Monday, November 23rd. The stock was sold at an average price of $26.38, for a total transaction of $120,741.26. Following the completion of the sale, the chief executive officer now directly owns 268,404 shares in the company, valued at $7,080,497.52. The disclosure for this sale can be found here. Over the last three months, insiders have sold 96,258 shares of company stock worth $3,218,261. Insiders own 2.64% of the company’s stock.
Establishment Labs Company Profile
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.
Featured Story: FinTech
Want to see what other hedge funds are holding ESTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Establishment Labs Holdings Inc. (NASDAQ:ESTA).
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.